Permira Partners with Marcucci Family, ADIA and Ampersand to Combine Kedrion and BPL
September 1, 2022
Funds advised by Permira, in partnership with the Marcucci family and supported by a subsidiary of ADIA and Ampersand Capital Partners, completed the joint acquisition and combination of Kedrion Biopharma and Bio Products Laboratory (BPL) to create a global leader in plasma derivatives and rare disease medicines. The combined company will be headquartered in Italy, generate over €1.1 billion in revenue, and expand its global footprint (including a ~75 US plasma center footprint); Ugo Di Francesco has been appointed CEO effective January 2023.
- Buyers
- Permira (funds advised by Permira), Marcucci family, Abu Dhabi Investment Authority (ADIA) - via a wholly-owned subsidiary, Ampersand Capital Partners
- Targets
- Kedrion Biopharma, Bio Products Laboratory (BPL)
- Industry
- Pharmaceuticals
- Location
- Tuscany, Italy
- Transaction Type
- Buyout
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.